Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved annual flu shot when tested in adults aged 50 years and older in a late-stage ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the company pulled its application for a combo flu/COVID-19 shot, saying it would ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna announced that in the Phase 1/2 study, mRNA-1083 appeared to achieve antibody titers similar to or greater than both the licensed flu shot and the updated Covid-19 vaccine.

Moderna presented early data from clinical trials of its mRNA-based flu vaccine. The shots didn’t generate more antibodies than shots already on the market.

Moderna started the first trial for its mRNA-based flu vaccine. The success of the mRNA COVID-19 vaccines accelerated work on other shots using the same approach.

Moderna said Wednesday that it has begun testing a flu vaccine as it seeks to expand the uses of the mRNA technology used in its COVID-19 vaccine. The first participants in an early-stage study ...

Moderna and Pfizer have plans to combine Covid-19 mRNA shots with those for flu and RSV in the years ahead if studies show that they're safe and effective.

(CNN) — Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in ...